Disease · MONDO_0100313
focal segmental glomerulosclerosis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. focal segmental glomerulosclerosis. Diseases, record MONDO_0100313. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0100313
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
FGS (focal glomerular sclerosis), FSGS, FSGS - focal segmental glomerulosclerosis, Focal and segmental glomerular sclerosis, Focal and segmental glomerulosclerosis, focal glomerulosclerosis, glomerulonephritis, focal sclerosing, glomerulosclerosis, glomerulosclerosis, focal, glomerulosclerosis, focal segmental
- Open Targets
- Highest stage of its drugs
- Phase 3, for 10 of its 45 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs45
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| SPARSENTAN | CHEMBL539423 | Small molecule | Phase 3 | ClinicalTrials.gov and TTD | 4 | 3 | 3 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| IRBESARTAN | CHEMBL1513 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CHLORAMBUCIL | CHEMBL515 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CORTICOTROPIN | CHEMBL1201610 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| CYCLOSPORINE | CHEMBL160 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| REPAGERMANIUM | CHEMBL2107883 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 45
See all 45 drugsTargets90
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 3 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 2 | Type-1 angiotensin II receptor antagonist | Phase 3 | https://conductscience.org/library/genes/185 | Drugs and targets |
| EDNRA | Endothelin-1 receptor | 2 | Endothelin receptor ET-A antagonist | Phase 3 | https://conductscience.org/library/genes/1909 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 2 | FK506-binding protein 1A inhibitor | Phase 2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor gamma | 2 | Peroxisome proliferator-activated receptor gamma agonist; Peroxisome proliferator-activated receptor gamma antagonist | Phase 2 | https://conductscience.org/library/genes/5468 | Drugs and targets |
| ALDH5A1 | Succinate-semialdehyde dehydrogenase, mitochondrial | 1 | Succinate semialdehyde dehydrogenase inhibitor | Phase 2/3 | https://conductscience.org/library/genes/7915 | Drugs and targets |
| ATP4A | Potassium-transporting ATPase | 1 | Potassium-transporting ATPase inhibitor | Unknown | https://conductscience.org/library/genes/495 | Drugs and targets |
| ATP4B | Potassium-transporting ATPase | 1 | Potassium-transporting ATPase inhibitor | Unknown | https://conductscience.org/library/genes/496 | Drugs and targets |
| BTK | Tyrosine-protein kinase BTK | 1 | Tyrosine-protein kinase BTK inhibitor | Phase 2 | https://conductscience.org/library/genes/695 | Drugs and targets |
| C3 | Complement C3 | 1 | Complement C3 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/718 | Drugs and targets |
1 to 10 of 90
See all 90 targetsTrials49
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03493685 | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) | Phase 3 | 371 | 2024-04-30 | Focal Segmental Glomerulosclerosis | IRBESARTAN, SPARSENTAN | Its record names the disease | ClinicalTrials.gov |
| NCT01613118 | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis | Phase 2 | 109 | 2021-07-27 | Focal Segmental Glomerulosclerosis | IRBESARTAN, SPARSENTAN | Its record names the disease | ClinicalTrials.gov |
| NCT03366337 | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX | Phase 2 | 103 | 2022-01-18 | IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney | BARDOXOLONE METHYL | Its record names the disease | ClinicalTrials.gov |
| NCT03536754 | A Study of CCX140-B in Subjects With FSGS | Phase 2 | 46 | 2023-12-05 | FSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis | ILACIRNON | Its record names the disease | ClinicalTrials.gov |
| NCT02592798 | Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) | Phase 2 | 36 | 2021-03-05 | Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease | ABATACEPT | Its record names the disease | ClinicalTrials.gov |
| NCT00814255 | Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial | Phase 2 | 32 | 2016-07-11 | Focal Segmental Glomerulosclerosis | ADALIMUMAB, GALACTOSE | Its record names the disease | ClinicalTrials.gov |
| NCT01164098 | Rituximab to Prevent Recurrence of Proteinuria | Phase 3 | 30 | 2018-09-20 | FSGS, Proteinuria | RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00001959 | Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis) | Phase 2 | 21 | 2012-06-01 | Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria | PIRFENIDONE | Its record names the disease | ClinicalTrials.gov |
| NCT02000440 | A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 | 17 | 2017-06-12 | Glomerulosclerosis, Focal Segmental | LOSMAPIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT04340362 | Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis | Phase 2 | 16 | 2023-07-10 | Glomerulosclerosis, Focal Segmental | INAXAPLIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 49
See all 49 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sparsentan vs Irbesartan: deaths from any cause | 4 of 184 | 3 of 187 | 371 | NCT03493685 | Trial comparisons |
| Sparsentan vs Irbesartan: serious adverse events | 68 of 184 | 82 of 187 | 371 | NCT03493685 | Trial comparisons |
| Rituximab vs No Rituximab: deaths from any cause | 0 of 15 | 0 of 15 | 30 | NCT01164098 | Trial comparisons |
| Rituximab vs No Rituximab: serious adverse events | 2 of 15 | 0 of 15 | 30 | NCT01164098 | Trial comparisons |
| 2 Doses Every 2 Weeks Arm vs 4 Doses Every 4 Weeks Arm: serious adverse events | 1 of 4 | 2 of 4 | 8 | NCT00065611 | Trial comparisons |
Papers from its trials30
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100313
GET https://conductscience.org/api/diseases/v1/MONDO_0100313/drugs?page=2